Did Mass. throw a monkey wrench in its life sciences bill?
Two top biotech players in Massachusetts are putting a spotlight on a controversial provision of the state's new $1 billion support program for the industry. According to John Maraganore, CEO of Alnylam Pharmaceuticals, and Amir Nashat, general partner of Polaris Venture Partners, the state's initiative gives one company the right to "cherry-pick all public sector-funded advances produced at a Massachusetts academic institution."
Writing in the Boston Herald, the two say the rule will dramatically reduce academic groups' ability to spin off new companies and reduce the appetite of venture capital groups for new investments. And they note that California and other states got it right with their programs. Now it's up to the Massachusetts Life Sciences Center to correct the situation.
- read the op-ed piece in the Boston Herald
Related Articles:
Mass. ponders how to hand out $500M
Massachusetts gift bill now law
Mass. Governor to sign $1B incentives plan
Are Mass. lawmakers 'anti-biopharmaceutical'?
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
